Article
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial.
Circulation. Heart failure - 1 Jun 2025
Topriceanu Constantin-Cristian, Vissing Christoffer Rasmus, Axelsson Raja Anna, Day Sharlene M, Russell Mark W, Zahka Kenneth, Pereira Alexandre C, Colan Steven D, Murphy Anne M, Canter Charles, Bach Richard G, Wheeler Matthew T, Rossano Joseph W, Owens Anjali T, Mestroni Luisa, Taylor Matthew R G, Moon James C, Captur Gabriella, Patel Amit R, Wilmot Ivan, Soslow Jonathan H, Becker Jason R, Seidman Christine E, Lakdawala Neal K, Bundgaard Henning, Tahir Usman A, Ho Carolyn Y
Abstract excerpt
BACKGROUND: In hypertrophic cardiomyopathy (HCM), the mechanisms through which pathogenic sarcomere variants (G+) lead to left ventricular hypertrophy (LVH) are not understood. METHODS: VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) was a multicenter, double-blind, placebo-controlled, randomized trial testing valsartan's ability to attenuate phenotypic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.